Cpg oligodeoxynucleotide

Cpg oligodeoxynucleotide has been studied in 7 papers since 2017: none in people yet, 5 in animals, 2 reviews; 1 in the past year. The research so far is in animals. The newest story, Oct 28, 2026: “Vaccine eased metabolic problems and extended life in mice”.

InterventionEarly phase 1

7 papers study itUpdated

1 new paper in 30 daysSee all 7 papers on cpg oligodeoxynucleotide

At a glance

2 trials, none about aging, 1 with no results posted.

Cells, worms or flies, mice and humans: nothing yet.
  • 2 trials, none about aging, 1 with no results posted
  • Animals5

Has cpg oligodeoxynucleotide been tested in people?

0 of 2 about aging

2 trials are registered, but no study of it in people has been published yet.

In trials

  • Breast neoplasm

    Early phase 1Completed1 trial

  • Triple negative breast neoplasm

    Early phase 1Completed1 trial

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 01 paper in 12 months
Advanced Science

Vaccine eased metabolic problems and extended life in mice

Experiments across multiple aging mouse models found that a vaccine cleared targeted fat cells in senescence, a state in which cells stop dividing.Experiments across multiple aging mouse models found that a vaccine cleared targeted fat cells in senescence, a state in which cells stop dividing.

Mouse studyInterventions